Eterna Therapeutics Inc. Files Amendment to Annual Report
Ticker: ERNAW · Form: 10-K/A · Filed: Mar 18, 2024 · CIK: 748592
| Field | Detail |
|---|---|
| Company | Eterna Therapeutics Inc. (ERNAW) |
| Form Type | 10-K/A |
| Filed Date | Mar 18, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.005 |
| Sentiment | neutral |
Sentiment: neutral
Topics: Eterna Therapeutics, 10-K/A, SEC Filing, Amendment, Nasdaq
TL;DR
<b>Eterna Therapeutics Inc. has filed an amendment to its 2023 annual report, providing updated information.</b>
AI Summary
Eterna Therapeutics Inc. (ERNAW) filed a Amended Annual Report (10-K/A) with the SEC on March 18, 2024. Eterna Therapeutics Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023. The company's common stock is traded on the Nasdaq Capital Market under the ticker symbol ERNA. Eterna Therapeutics Inc. was formerly known as Brooklyn ImmunoTherapeutics, Inc. until March 25, 2021. The company was also formerly known as NTN BUZZTIME INC and NTN COMMUNICATIONS INC. The filing was made on March 18, 2024.
Why It Matters
For investors and stakeholders tracking Eterna Therapeutics Inc., this filing contains several important signals. This amendment indicates that Eterna Therapeutics Inc. is providing updated or corrected information for its fiscal year 2023, which is crucial for investors to have the most accurate data. The filing confirms the company's listing on the Nasdaq Capital Market, a key detail for shareholders and potential investors tracking its stock performance.
Risk Assessment
Risk Level: low — Eterna Therapeutics Inc. shows low risk based on this filing. The filing is an amendment to a previous report, suggesting it's for clarification or correction rather than a new material event.
Analyst Insight
Review the specific changes made in this 10-K/A filing to understand any updated disclosures or corrections relevant to Eterna Therapeutics Inc.'s operations and financial standing.
Key Numbers
- 2023-12-31 — Fiscal Year End (Reported fiscal year end)
- 2024-03-18 — Filing Date (Date the amendment was filed)
- 1-11460 — Commission File Number (SEC commission file number for the registrant)
- 0000748592 — Central Index Key (SEC central index key for the registrant)
Key Players & Entities
- Eterna Therapeutics Inc. (company) — Registrant name
- Nasdaq Capital Market (company) — Exchange where common stock is registered
- ERNA (company) — Trading symbol for common stock
- Brooklyn ImmunoTherapeutics, Inc. (company) — Former company name
- NTN BUZZTIME INC (company) — Former company name
- NTN COMMUNICATIONS INC (company) — Former company name
- 2023-12-31 (date) — Fiscal year end
- 2024-03-18 (date) — Filing date
FAQ
When did Eterna Therapeutics Inc. file this 10-K/A?
Eterna Therapeutics Inc. filed this Amended Annual Report (10-K/A) with the SEC on March 18, 2024.
What is a 10-K/A filing?
A 10-K/A is a amendment to a previously filed annual report, correcting or updating financial statements or disclosures. This particular 10-K/A was filed by Eterna Therapeutics Inc. (ERNAW).
Where can I read the original 10-K/A filing from Eterna Therapeutics Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Eterna Therapeutics Inc..
What are the key takeaways from Eterna Therapeutics Inc.'s 10-K/A?
Eterna Therapeutics Inc. filed this 10-K/A on March 18, 2024. Key takeaways: Eterna Therapeutics Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023.. The company's common stock is traded on the Nasdaq Capital Market under the ticker symbol ERNA.. Eterna Therapeutics Inc. was formerly known as Brooklyn ImmunoTherapeutics, Inc. until March 25, 2021..
Is Eterna Therapeutics Inc. a risky investment based on this filing?
Based on this 10-K/A, Eterna Therapeutics Inc. presents a relatively low-risk profile. The filing is an amendment to a previous report, suggesting it's for clarification or correction rather than a new material event.
What should investors do after reading Eterna Therapeutics Inc.'s 10-K/A?
Review the specific changes made in this 10-K/A filing to understand any updated disclosures or corrections relevant to Eterna Therapeutics Inc.'s operations and financial standing. The overall sentiment from this filing is neutral.
How does Eterna Therapeutics Inc. compare to its industry peers?
Eterna Therapeutics Inc. operates in the pharmaceutical preparations industry.
Are there regulatory concerns for Eterna Therapeutics Inc.?
The filing is made under the Securities Exchange Act of 1934, specifically Section 13 or 15(d), and adheres to SEC regulations for annual reports and amendments.
Industry Context
Eterna Therapeutics Inc. operates in the pharmaceutical preparations industry.
Regulatory Implications
The filing is made under the Securities Exchange Act of 1934, specifically Section 13 or 15(d), and adheres to SEC regulations for annual reports and amendments.
What Investors Should Do
- Review the full 10-K/A filing for specific details on any amendments made to the original 10-K.
- Verify Eterna Therapeutics Inc.'s current status and trading information on the Nasdaq Capital Market.
- Research the company's historical name changes to understand its corporate evolution.
Key Dates
- 2024-03-18: Filing of 10-K/A Amendment — Provides updated information for the fiscal year 2023.
- 2023-12-31: Fiscal Year End — The period covered by the annual report.
- 2021-03-25: Name Change — Date Eterna Therapeutics Inc. changed from Brooklyn ImmunoTherapeutics, Inc.
Year-Over-Year Comparison
This is an amendment (10-K/A) to the previous annual report, indicating updates or corrections to the information previously filed for the fiscal year ended December 31, 2023.
Filing Stats: 1,151 words · 5 min read · ~4 pages · Grade level 12.5 · Accepted 2024-03-18 07:30:39
Key Financial Figures
- $0.005 — ange on Which Registered Common Stock, $0.005 par value ERNA Nasdaq Capital Marke
Filing Documents
- ef20024302_10ka.htm (10-K/A) — 45KB
- ef20024302_ex23-1.htm (EX-23.1) — 3KB
- ef20024302_ex31-1.htm (EX-31.1) — 5KB
- ef20024302_ex31-2.htm (EX-31.2) — 5KB
- image00002.jpg (GRAPHIC) — 3KB
- 0001140361-24-013709.txt ( ) — 256KB
- erna-20231231.xsd (EX-101.SCH) — 4KB
- erna-20231231_lab.xml (EX-101.LAB) — 28KB
- erna-20231231_pre.xml (EX-101.PRE) — 20KB
- ef20024302_10ka_htm.xml (XML) — 7KB
SIGNATURES
SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized . ETERNA THERAPEUTICS INC. Date: March 18, 2024 By: /s/ Sandra Gurrola Sandra Gurrola Senior Vice President of Finance (Principal Financial Officer and Principal Accounting Officer) 3